131 related articles for article (PubMed ID: 37738672)
1. Communicating and understanding statistical measures when quantifying the between-group difference in competing risks.
Wu H; Zhang C; Hou Y; Chen Z
Int J Epidemiol; 2023 Dec; 52(6):1975-1983. PubMed ID: 37738672
[TBL] [Abstract][Full Text] [Related]
2. Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost.
Wu H; Yuan H; Yang Z; Hou Y; Chen Z
Am J Epidemiol; 2022 Jan; 191(1):163-172. PubMed ID: 34550319
[TBL] [Abstract][Full Text] [Related]
3. The use of restricted mean time lost under competing risks data.
Lyu J; Hou Y; Chen Z
BMC Med Res Methodol; 2020 Jul; 20(1):197. PubMed ID: 32711456
[TBL] [Abstract][Full Text] [Related]
4. Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models.
Mozumder SI; Rutherford MJ; Lambert PC
BMC Med Res Methodol; 2021 Mar; 21(1):52. PubMed ID: 33706711
[TBL] [Abstract][Full Text] [Related]
5. Estimation and modeling of the restricted mean time lost in the presence of competing risks.
Conner SC; Trinquart L
Stat Med; 2021 Apr; 40(9):2177-2196. PubMed ID: 33567477
[TBL] [Abstract][Full Text] [Related]
6. Analysis and design of randomised clinical trials involving competing risks endpoints.
Tai BC; Wee J; Machin D
Trials; 2011 May; 12():127. PubMed ID: 21595883
[TBL] [Abstract][Full Text] [Related]
7. causalCmprsk: An R package for nonparametric and Cox-based estimation of average treatment effects in competing risks data.
Vakulenko-Lagun B; Magdamo C; Charpignon ML; Zheng B; Albers MW; Das S
Comput Methods Programs Biomed; 2023 Dec; 242():107819. PubMed ID: 37774426
[TBL] [Abstract][Full Text] [Related]
8. The importance of censoring in competing risks analysis of the subdistribution hazard.
Donoghoe MW; Gebski V
BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
[TBL] [Abstract][Full Text] [Related]
9. Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry.
Lau B; Cole SR; Gange SJ
Stat Med; 2011 Mar; 30(6):654-65. PubMed ID: 21337360
[TBL] [Abstract][Full Text] [Related]
10. Quantifying time-varying cause-specific hazard and subdistribution hazard ratios with competing risks data.
Diao G; Ibrahim JG
Clin Trials; 2019 Aug; 16(4):363-374. PubMed ID: 31165631
[TBL] [Abstract][Full Text] [Related]
11. Kidney Graft Failure and Patient Survival Modelling Based on Competing Risks Under Nonproportional Hazards.
Valenta Z; Skrabaka D; Owczarek AJ; Kolonko A; Król R; Więcek A; Ziaja J
Transplant Proc; 2022 May; 54(4):940-947. PubMed ID: 35450721
[TBL] [Abstract][Full Text] [Related]
12. Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.
Hsu JY; Roy JA; Xie D; Yang W; Shou H; Anderson AH; Landis JR; Jepson C; Wolf M; Isakova T; Rahman M; Feldman HI;
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1181-1189. PubMed ID: 28242844
[TBL] [Abstract][Full Text] [Related]
13. Modelling two cause-specific hazards of competing risks in one cumulative proportional odds model?
Ohneberg K; Schumacher M; Beyersmann J
Stat Med; 2017 Nov; 36(27):4353-4363. PubMed ID: 28833435
[TBL] [Abstract][Full Text] [Related]
14. Analysing and interpreting competing risk data.
Pintilie M
Stat Med; 2007 Mar; 26(6):1360-7. PubMed ID: 16900575
[TBL] [Abstract][Full Text] [Related]
15. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
Tai BC; Chen ZJ; Machin D
Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
[TBL] [Abstract][Full Text] [Related]
16. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
Austin PC; Fine JP
Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
[TBL] [Abstract][Full Text] [Related]
17. Trials using composite outcomes neglect the presence of competing risks: a methodological survey of cardiovascular studies.
Kim H; Shahbal H; Parpia S; Averbuch T; Van Spall HGC; Thabane L; Ma J
J Clin Epidemiol; 2023 Aug; 160():1-13. PubMed ID: 37245700
[TBL] [Abstract][Full Text] [Related]
18. Standard and competing risk analysis of the effect of albuminuria on cardiovascular and cancer mortality in patients with type 2 diabetes mellitus.
Feakins BG; McFadden EC; Farmer AJ; Stevens RJ
Diagn Progn Res; 2018; 2():13. PubMed ID: 31093562
[TBL] [Abstract][Full Text] [Related]
19. Direct likelihood inference and sensitivity analysis for competing risks regression with missing causes of failure.
Moreno-Betancur M; Rey G; Latouche A
Biometrics; 2015 Jun; 71(2):498-507. PubMed ID: 25761785
[TBL] [Abstract][Full Text] [Related]
20. Subdistribution hazard models for competing risks in discrete time.
Berger M; Schmid M; Welchowski T; Schmitz-Valckenberg S; Beyersmann J
Biostatistics; 2020 Jul; 21(3):449-466. PubMed ID: 30418529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
